drugset / Trial / NCT02211079
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effects of single and multiple once daily doses of 50 milligram (mg) of JNJ-54861911 on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over time) of caffeine, midazolam, and tolbutamide in healthy male participants.
Timeline
- Start
- 2014-09
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atabecestat | Small molecule | 50 mg | Oral |
| Subject | Caffeine | Small molecule | 100 mg | Oral |
| Subject | Midazolam | Small molecule | 2 mg | Oral |
| Subject | Tolbutamide | Small molecule | 500 mg | Oral |
Indications
No indication recorded.